TN2013000386A1 - Suspension type topical formulations comprising cyclic depsipeptide - Google Patents

Suspension type topical formulations comprising cyclic depsipeptide

Info

Publication number
TN2013000386A1
TN2013000386A1 TNP2013000386A TN2013000386A TN2013000386A1 TN 2013000386 A1 TN2013000386 A1 TN 2013000386A1 TN P2013000386 A TNP2013000386 A TN P2013000386A TN 2013000386 A TN2013000386 A TN 2013000386A TN 2013000386 A1 TN2013000386 A1 TN 2013000386A1
Authority
TN
Tunisia
Prior art keywords
cyclic depsipeptide
suspension type
topical formulations
type topical
compositions
Prior art date
Application number
TNP2013000386A
Other languages
English (en)
Inventor
Claire Haug
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46148908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000386(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2013000386A1 publication Critical patent/TN2013000386A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2013000386A 2011-04-20 2013-09-25 Suspension type topical formulations comprising cyclic depsipeptide TN2013000386A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477297P 2011-04-20 2011-04-20
PCT/IB2012/051946 WO2012143868A1 (fr) 2011-04-20 2012-04-18 Formulations topiques de type suspension comprenant un depsipeptide cyclique

Publications (1)

Publication Number Publication Date
TN2013000386A1 true TN2013000386A1 (en) 2015-01-20

Family

ID=46148908

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000386A TN2013000386A1 (en) 2011-04-20 2013-09-25 Suspension type topical formulations comprising cyclic depsipeptide

Country Status (21)

Country Link
US (2) US8680054B2 (fr)
EP (1) EP2699231B1 (fr)
JP (1) JP5906304B2 (fr)
KR (1) KR101612170B1 (fr)
CN (1) CN103476396B (fr)
AR (1) AR086109A1 (fr)
AU (1) AU2012245960B2 (fr)
BR (1) BR112013026698A2 (fr)
CA (1) CA2833326A1 (fr)
CL (1) CL2013003036A1 (fr)
EA (1) EA201391555A1 (fr)
ES (1) ES2651639T3 (fr)
GT (1) GT201300257A (fr)
IL (1) IL228863A0 (fr)
MA (1) MA35158B1 (fr)
MX (1) MX338156B (fr)
PE (1) PE20141068A1 (fr)
SG (1) SG11201402441WA (fr)
TN (1) TN2013000386A1 (fr)
TW (1) TW201247218A (fr)
WO (1) WO2012143868A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183273B1 (fr) 2007-08-17 2017-04-05 Novartis AG Depsipeptides cycliques
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9226890B1 (en) 2013-12-10 2016-01-05 Englewood Lab, Llc Polysilicone base for scar treatment
CN108888590A (zh) * 2018-08-06 2018-11-27 江苏知原药业有限公司 包含他克莫司的混悬类型的局部制剂
WO2021178834A1 (fr) * 2020-03-06 2021-09-10 LifeMax Laboratories, Inc. Formulations pharmaceutiques topiques d'un depsipeptide cyclique

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043252C2 (de) 1980-11-15 1982-12-02 Degussa Ag, 6000 Frankfurt Cyclische Acetale von N-Acylglutaminsäure -γ- semialdehyden, Verfahren zu deren Herstellung und ihre Verwendung
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE4421113A1 (de) 1994-06-16 1995-12-21 Biotechnolog Forschung Gmbh Chondramide, Gewinnungsverfahren, Mittel mit Chondramiden und Mischkultur zur Chondramid-Gewinnung
DE19828043A1 (de) 1998-06-24 1999-12-30 Bayer Ag Ektoparasitizide Mittel
JP2000154198A (ja) 1998-11-20 2000-06-06 Nisshin Flour Milling Co Ltd 環状デプシペプチドの固相合成方法及びその中間体
JP2001131085A (ja) * 1999-08-25 2001-05-15 Saitama Daiichi Seiyaku Kk 経皮・経粘膜吸収用の医薬組成物
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
US20040110228A1 (en) 2002-04-01 2004-06-10 Mcalpine Shelli R. Combinatorial organic synthesis of unique biologically active compounds
KR101099409B1 (ko) 2003-06-06 2011-12-27 아렉시스 악티에볼라그 피부 상태 또는 암 치료를 위한 scce 저해제로서의융합된 헤테로사이클 화합물의 용도
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
WO2005075667A1 (fr) 2004-02-03 2005-08-18 Bayer Healthcare Ag Methodes de diagnostic et de traitement de maladies associees a la kallikreine 7 (klk7)
AU2007220042A1 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
EP2183273B1 (fr) * 2007-08-17 2017-04-05 Novartis AG Depsipeptides cycliques
EP2183270B1 (fr) 2007-08-17 2014-12-17 Novartis AG Utilisation de dépsipeptides cycliques pour inhiber la kallikréine 7
DE102007052391A1 (de) 2007-10-31 2009-05-07 Henkel Ag & Co. Kgaa Mattwachs
JP2010241784A (ja) * 2008-06-19 2010-10-28 Mitsubishi Tanabe Pharma Corp 経皮投与製剤
US20110112121A1 (en) * 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
US20120064013A1 (en) 2010-02-03 2012-03-15 David Marcos Foamable topical composition
KR101004362B1 (ko) 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 TNF-α와 TWEAK 이중 길항제
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
ES2720648T3 (es) 2011-01-24 2019-07-23 Anterios Inc Composiciones de nanopartículas
WO2012103038A2 (fr) 2011-01-24 2012-08-02 Anterios, Inc. Compositions de nanoparticules, leurs formulations et leurs utilisations
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates

Also Published As

Publication number Publication date
CA2833326A1 (fr) 2012-10-26
EP2699231B1 (fr) 2017-09-13
JP5906304B2 (ja) 2016-04-20
AU2012245960A1 (en) 2013-10-17
US20120270796A1 (en) 2012-10-25
PE20141068A1 (es) 2014-09-04
AR086109A1 (es) 2013-11-20
KR20130133295A (ko) 2013-12-06
ES2651639T3 (es) 2018-01-29
SG11201402441WA (en) 2014-09-26
IL228863A0 (en) 2013-12-31
MX338156B (es) 2016-04-05
EP2699231A1 (fr) 2014-02-26
CL2013003036A1 (es) 2014-04-04
TW201247218A (en) 2012-12-01
EA201391555A1 (ru) 2014-11-28
US8680054B2 (en) 2014-03-25
US20140162959A1 (en) 2014-06-12
US9114110B2 (en) 2015-08-25
CN103476396B (zh) 2015-08-05
CN103476396A (zh) 2013-12-25
MA35158B1 (fr) 2014-06-02
JP2014512377A (ja) 2014-05-22
MX2013012187A (es) 2013-11-04
AU2012245960B2 (en) 2014-09-25
KR101612170B1 (ko) 2016-04-12
BR112013026698A2 (pt) 2016-12-27
GT201300257A (es) 2015-02-19
NZ615551A (en) 2015-08-28
WO2012143868A1 (fr) 2012-10-26

Similar Documents

Publication Publication Date Title
TN2013000386A1 (en) Suspension type topical formulations comprising cyclic depsipeptide
MX2013001677A (es) Formulaciones estables de linaclotida.
MX2019003693A (es) Formulaciones de insulina de accion prolongada.
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
MX341324B (es) Polipeptidos.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
IN2012DN00239A (fr)
TR201009167A2 (tr) Sefalosporin içeren farmasötik granüller.
MX342859B (es) Polisacarido de las semillas de tamarindo para usarse en el tratamiento de enfermedades inflamatorias.
LT2012092A (lt) Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
EA201490573A1 (ru) Соединение бензотиазолона
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
MX357704B (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
WO2011093831A3 (fr) Formulations effervescentes contenant du cefprosil comme principe actif
IN2014DN10134A (fr)
EA201492280A1 (ru) Стабильный состав пексиганана
WO2012007758A3 (fr) Formulations pharmaceutiques
TR201010859A2 (tr) Sefdinir içeren tablet formları.
TR201009166A2 (tr) Sefdinir içeren farmasötik bileşim için üretim yöntemi
TR201009165A2 (tr) Sefdinir içeren tabletler
EA201190243A1 (ru) Стабильная фармацевтическая композиция флударабина фосфата